Results 141 to 150 of about 71,298 (290)

Long‐term outcomes of children with ulcerative colitis after acute severe colitis: A GETAID pédiatrique multicenter study

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Acute severe colitis (ASC) is a frequent and severe complication of ulcerative colitis (UC) with a high risk of colectomy. Effects of immunosuppressants and anti–tumor necrosis factor (anti‐TNF) agents on the risk of colectomy remain debated. We wished to study the evolution of French pediatric‐onset UC patients after ASC.
Manon Cochet   +18 more
wiley   +1 more source

Azathioprine in Psoriasis [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1973
openaire   +2 more sources

Bowel ultrasound scan in the management of pediatric moderate ulcerative colitis: The applicability of international bowel ultrasound segmental activity score

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To evaluate bowel ultrasound (BUS) findings and the diagnostic and prognostic performance of international bowel ultrasound segmental activity score (IBUS‐SAS) in children with moderate ulcerative colitis (UC), including its accuracy for assessing endoscopic activity and predicting clinical remission and colectomy within 12 months ...
Martina Di Benedetto   +8 more
wiley   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan   +2 more
wiley   +1 more source

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange   +4 more
wiley   +1 more source

Cochlear Implantation in Autoimmune Inner‐Ear Disease: Outcome and Patient‐Reported Benefit

open access: yesThe Laryngoscope, EarlyView.
This study demonstrates that patients with secondary autoimmune inner‐ear disease (AIED) achieve significant improvements in speech perception and quality of life following cochlear implantation. Although AIED patients may show slightly lower performance in noisy environments compared to controls, their subjective hearing benefit converges with matched
Merete Hartmann   +4 more
wiley   +1 more source

Guidelines for prescribing azathioprine in dermatology

open access: yes
Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications.
Reynolds NJ, Anstey AV, Wakelin S
core  

Contribution of Glutathione-S-Transferases to the Pharmacogenetics of Azathioprine

open access: yes, 2015
Azathioprine is a purine antimetabolite drug commonly used as immunomodulator in the treatment of various chronic inflammatory diseases, such as inflammatory bowel disease (IBD).
VENTURA, ALESSANDRO   +9 more
core  

A Case of Azathioprine Induced Warfarin Resistance in Behçet’s Disease [PDF]

open access: yes, 2015
Behçet’s disease is characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. Thrombosis associated with vascular inflammation in patients with Behçet’s disease presents various clinical symptoms.
임동우   +3 more
core  

Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six‐week cyclic regimen may be associated with a “wearing‐off” effect and disease fluctuations. We evaluated the non‐cyclic administration
Marc Abi Aoun   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy